Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
Age
0–0
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Is a full-term infant approximately 2 months of age at time of obtaining the informed consent.
You may not be if
Had prior administration of any pneumococcal vaccine.
Has a known or suspected hypersensitivity to AFX3772, PCV13, PCV20 or any components of the formulations used.
Has a known or suspected immunodeficiency or other conditions associated with immunosuppression that may require immunosuppressive drugs. In addition, the participant's biological mother has known HIV infection or known to be hepatitis B surface antigen positive.
Has any clinically significant allergic condition or history prior to the first vaccination for primary immunization series.
Has a history of microbiologically proven invasive disease caused by S. pneumoniae.
Has received immunoglobulins.
Has a bleeding diathesis or condition associated with prolonged bleeding that would contraindicate intramuscular injection.
Has received systemic corticosteroids for a period of more than 14 days and has not completed the treatment for at least 30 days before study vaccine.
